Senolytics in human trials: a systematic review of six completed studies
A systematic review of six completed human clinical studies found preliminary functional and biomarker effects from senescence-targeting drugs, but evidence is insufficient for clinical efficacy or long-term safety. [1]
Automatic summary · not editorially reviewed
The key findings
Six completed human clinical studies were included in the evidence synthesis, plus one ongoing trial identified separately. [1]
Dasatinib plus quercetin showed preliminary improvements in selected functional outcomes and reductions in senescence-associated biomarkers. [1]
Evidence remains insufficient to establish clinical efficacy or long-term safety of senescence-targeting drugs. [1]
The source at a glance
- Study type / format
- Systematic review and narrative synthesis (abstract)
- Population / context
- Human participants in randomized and nonrandomized clinical trials and pilot studies of pharmacological senescence-targeting interventions.
- Summary based on
- Study abstract
- Original publication
- October 5, 2026
Six human trials on senescence-targeting drugs
The review asked whether pharmacological interventions targeting cellular senescence have measurable effects in people. Cellular senescence means cells stop dividing irreversibly and release inflammatory signals, called the senescence-associated secretory phenotype. The authors followed PRISMA 2020 guidance and included randomized and nonrandomized clinical trials and pilot studies in humans that reported clinical, functional or senescence-associated outcomes. Six completed clinical studies entered the evidence synthesis, and one additional ongoing trial was identified separately.
Supporting source [1]
Preliminary effects of senolytics and senomorphics
Senolytic interventions, especially dasatinib plus quercetin, showed preliminary improvements in selected functional outcomes and reductions in senescence-associated biomarkers. Senomorphic and mTOR-targeting interventions showed effects on selected tissue and immune-related outcomes. Reported adverse events were generally mild or manageable. The authors stress that small sample sizes and short follow-up limited assessment of uncommon and long-term safety risks, so these strategies remain investigational rather than established therapies.
Supporting source [1]
Evidence gap: efficacy and long-term safety unproven
The review concludes that pharmacological targeting of cellular senescence is feasible and may produce measurable biological and functional effects in humans. However, the evidence remains insufficient to establish clinical efficacy or long-term safety. The authors call for larger, adequately powered randomized trials with standardized senescence biomarkers, clinically meaningful outcomes, longer follow-up and systematic safety assessment. This is an abstract; the full text was not reviewed.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The review itself notes small sample sizes and short follow-up in the included studies, limiting assessment of uncommon and long-term safety risks.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Trivedi H, Tripathi S, Thacker J, Patil N, Shaikh S. · europepmc.org · October 5, 2026